Stock Financial Ratios


CERC / Cerecor Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.18
Volume182,400.00
Market Cap ($M)24.19
Enterprise Value ($M)4.36
Book Value ($M)0.21
Book Value / Share0.02
Price / Book1.09
NCAV ($M)1.46
NCAV / Share0.16
Price / NCAV1.08
Income Statement (mra) ($M)
Revenue0.00
EBITDA-16.08
Net Income-16.47
Balance Sheet (mrq) ($M)
Cash & Equivalents24.00
Cash / Share2.72
Assets28.20
Liabilities6.08
Quick Ratio1.31
Current Ratio1.31
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-6.43
Return on Assets (ROA)-2.86
Return on Equity (ROE)-79.57
Identifiers and Descriptors
CUSIP15671L109
Central Index Key (CIK)1534120
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)26.05
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Additional Paid In Capital Per Share8.74
Liabilities Per Share0.69
Equity Per Share2.51
Assets Other Non Current Per Share0.00
Cash Per Share2.72
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Liabilities Current Per Share0.55
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Minority Interest Per Share0.00
Assets Current Per Share3.18
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Liabilities And Stock Equity Per Share3.19
Inventory Raw Materials Per Share0.00
Retained Earnings Per Share-6.24
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Assets Per Share3.19
Cash And Equivalents Per Share2.72

Stock Research Report

Cerecor is a biopharmaceutical company that is developing innovative drug candidates to make a difference in the lives of patients with neurologic and psychiatric disorders. The company's lead drug candidate is CERC-301, which the company currently intend to explore as a novel treatment for orphan neurologic indications. The company also have two pre-clinical stage compounds, CERC-611 and CERC-406.

The company's portfolio of product candidates is summarized below:

  • CERC-301: Orphan Neurologic Diseases. CERC‑301 belongs to a class of compounds known as antagonists of the N‑methyl‑D‑aspartate, or NMDA, receptor, a receptor subtype of the glutamate neurotransmitter system that is responsible for controlling neurologic adaptation. The company believe CERC‑301 specifically blocks the NMDA receptor subunit 2B, or NR2B. Cerecor has conducted two Phase 2 studies with this drug candidate as a potential adjunctive treatment for major depressive disorders, or MDD, in which the company obs...
Click for full article

Related News Stories

Corporate News Blog - Cerecor Acquired TRx Pharmaceuticals

10h accesswire
LONDON, UK / ACCESSWIRE / November 21, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cerecor Inc. (NASDAQ: CERC), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=CERC. The Company announced on November 17, 2017, that it has signed an agreement to acquire TRx Pharmaceuticals LLC, including subsidiary Zylera Pharmaceuticals, LLC, and its franchise of commercial medications led by Poly-Vi-Flor® and Tri-Vi-Flor®. (70-0)

Your Daily Pharma Scoop: Synergy Must Buy, RedHill Positive Data, CTMX-AMGN Collaboration

2017-10-04 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (866-17)

BRIEF-Cerecor Inc says Uli Hacksell retires as CEO, president

2017-08-14 reuters
* Cerecor Inc says John Kaiser, chief business officer of Cerecor, has been appointed interim chief executive officer

Post «NMDA Receptor Targeting Offers New Hope For Severely Depressed» in blog BioNap

2017-07-10 bionap.whotrades
The psychiatric community may be on the verge of a paradigm shift when it comes to treating the severely depressed. New treatment options are desperately needed, because what is clear today is that generic antidepressants do not work for many patients. A 2007 report by the Agency for Healthcare Research and Quality (AHRQ) compared the effectiveness of first- and second-generation antidepressants by reviewing available literature and reported data from 187 randomized and/or placebo-controlled clinical trials.

CUSIP: 15671L109